|
1
|
Lossos IS and Morgensztern D: Prognostic
biomarkers in diffuse large B-Cell lymphoma. J Clin Oncol.
24:995–1007. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Westin JR and Fayad LE: Beyond R-CHOP and
the IPI in large-cell lymphoma: Molecular markers as an opportunity
for stratification. Curr Hematol Malig Rep. 4:218–224. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sandhu SK, Croce CM and Garzon R:
Micro-RNA expression and function in lymphomas. Adv Hematol.
2011:1–12. 2011. View Article : Google Scholar
|
|
4
|
Wang W and Luo YP: MicroRNAs in breast
cancer: Oncogene and tumor suppressors with clinical potential. J
Zhejiang Univ Sci B. 16:18–31. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Catuogno S, Esposito CL, Quintavalle C,
Cerchia L, Condorelli G and De Franciscis V: Recent advance in
biosensors for microRNAs detection incancer. Cancers (Basel).
3:1877–1898. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Di Lisio L, Martinez N, Montes-Moreno S,
Piris-Villaespesa M, Sanchez-Beato M and Piris P: The role of
miRNAs in the pathogenesis and diagnosis of B-cell lymphomas.
Blood. 120:1782–1790. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yu DC, Li QG, Ding XW and Ding YT:
Circulating microRNAs: Potential biomarkers for cancer. Int J Mol
Sci. 12:2055–2063. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bouchie A: First microRNA mimic enters
clinic. Nat Biotechnol. 31:5772013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lawrie CH: MicroRNAs and lymphomagenesis:
A functional review. Br J Haematol. 160:571–581. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Löffler D, Brocke-Heidrich K, Pfeifer G,
Stocsits C, Hackermüller J, Kretzschmar AK, Burger R, Gramatzki M,
Blumert C, Bauer K, et al: Interleukin-6 dependent survival of
multiple myeloma cells involves the Stat3-mediated induction of
microRNA-21 through a highly conserved enhancer. Blood.
110:1330–1333. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Meng F, Henson R, Wehbe-Janek H, Ghoshal
K, Jacob ST and Patel T: MicroRNA-21 regulates expression of the
PTEN tumor suppressor gene in human hepatocellular cancer.
Gastroenterology. 133:647–658. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Frankel LB, Christoffersen NR, Jacobsen A,
Lindow M, Krogh A and Lund AH: Programmed cell death 4 (PDCD4) is
an important functional target of the microRNA miR-21 in breast
cancer cells. J Biol Chem. 283:1026–1033. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chen C, Ridzon DA, Broomer AJ, Zhou Z, Lee
DH, Nguyen JT, Barbisin M, Xu NL, Mahuvakar VR, Andersen MR, et al:
Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic
Acids Res. 33:e1792005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Fang C, Zhu DX, Dong HJ, Zhou ZJ, Wang YH,
Liu L, Fan L, Miao KR, Liu P, Xu W and Li JY: Serum microRNAs are
promising novel biomarkers for diffuse large B cell lymphoma. Ann
Hematol. 91:553–559. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Roehle A, Hoefig KP, Repsilber D, Thorns
C, Ziepert M, Wesche KO, Thiere M, Loeffler M, Klapper W,
Pfreundschuh M, et al: MicroRNA signatures characterize diffuse
large B-cell lymphomas and follicular lymphomas. Br J Haematol.
142:732–744. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lawrie CH, Soneji S, Marafioti T, Cooper
CD, Palazzo S, Paterson JC, Cattan H, Enver T, Mager R, Boultwood
J, et al: Microrna expression distinguishes between germinal center
B cell-like and activated B cell-like subtypes of diffuse large B
cell lymphoma. Int J Cancer. 121:1156–1161. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Caramuta S, Lee L, Ozata DM, Akçakaya P,
Georgii-Hemming P, Xie H, Amini RM, Lawrie CH, Enblad G, Larsson C,
et al: Role of microRNAs and microRNA machinery in the pathogenesis
of diffuse large B-cell lymphoma. Blood Cancer J. 3:e1522013.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Di Lisio L, Sánchez-Beato M, Gómez-López
G, Rodríguez ME, Montes-Moreno S, Mollejo M, Menárguez J, Martínez
MA, Alves FJ, Pisano DG, et al: MicroRNA signatures in B-cell
lymphomas. Blood Cancer J. 2:e572012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Li C, Kim SW, Rai D, Bolla AR, Adhvaryu S,
Kinney MC, Robetorye RS and Aguiar RC: Copy number abnormalities,
MYC activity and the genetic fingerprint of normal B cells
mechanistically define the microRNA profile of diffuse large B-cell
lymphoma. Blood. 113:6681–6690. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhong H, Xu L, Zhong JH, Xiao F, Liu Q,
Huang HH and Chen FY: Clinical and prognostic significance of
miR-155 and miR-146a expression levels in
formalin-fixed/paraffin-embedded tissue of patients with diffuse
B-cell lymphoma. Exp Ther Med. 3:763–770. 2012.PubMed/NCBI
|
|
21
|
Metzler M, Wilda M, Busch K, Viehmann S
and Borkhardt A: High expression of precursor microRNA-155/BIC RNA
in children with Burkitt lymphoma. Genes Chromosomes Cancer.
39:167–169. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Linnstaedt SD, Gottwein E, Skalsky RL,
Luftig MA and Cullen BR: Virally induced cellular MicroRNA miR-155
plays a key role in B-Cell immortalization by Epstein-Barr virus. J
Virol. 84:11670–11678. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lu F, Weidmer A, Liu CG, Volinia S, Croce
CM and Lieberman PM: Epstein-Barr virus-induced miR-155 attenuates
NF-kappaB signaling and stabilizes latent virus persistence. J
Virol. 82:10436–10443. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Rai D, Kim SW, McKeller MR, Dahia PL and
Aguiar RC: Targeting of SMAD5 links microRNA-155 to the TGF-beta
pathway and lymphomagenesis. Proc Natl Acad Sci USA. 107:3111–3116.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yin Q, McBride J, Fewell C, Lacey M, Wang
X, Lin Z, Cameron J and Flemington EK: MicroRNA-155 is an
Epstein-Barr Virus induced gene that modulates Epstein Barr virus
regulated gene expression pathways. J Virol. 82:5295–5306. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Bolisetty MT, Dy G, Tam W and Beemon KL:
Reticuloendotheliosis virus strain T induces miR-155, which targets
JARID2 and promotes cell survival. J Virol. 83:12009–12017. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Eis PS, Tam W, Sun L, Chadburn A, Li Z,
Gomez MF, Lund E and Dahlberg JE: Accumulation of miR-155 and BIC
RNA in human B cell lymphomas. Proc Natl Acad Sci USA.
102:3627–3632. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Rai D, Karanti S, Jung I, Dahia PL and
Aguiar RC: Coordinated expression of microRNA-155 and predicted
target genes in diffuse large B-cell lymphoma. Cancer Genet
Cytogenet. 181:8–15. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Martín-Pérez D, Vargiu P, Montes-Moreno S,
León EA, Rodríguez-Pinilla SM, Lisio LD, Martínez N, Rodríguez R,
Mollejo M, Castellvi J, et al: Epstein-Barr virus microRNAs repress
BCL6 expression in diffuse large B-cell lymphoma. Leukemia.
26:180–183. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Huang X, Shen Y, Liu M, Bi C, Jiang C,
Iqbal J, McKeithan TW, Chan WC, Ding SJ and Fu K: Quantitative
proteomics reveals that miR-155 regulates the PI3K-AKT pathway in
diffuse large B-cell lymphoma. Am J Pathol. 181:26–33. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Pan X, Wang ZX and Wang R: MicroRNA-21: A
novel therapeutic target in human cancer. Cancer Biol Ther.
10:1224–1232. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Si ML, Zhu S, Wu H, Lu Z, Wu F and Mo YY:
MiR-21-mediated tumor growth. Oncogene. 26:2799–2803. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Chan JA, Krichevsky AM and Kosik KS:
MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells.
Cancer Res. 65:6029–6033. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Cheng AM, Byrom MW, Shelton J and Ford LP:
Antisense inhibition of human miRNAs and indications for an
involvement of miRNA in cell growth and apoptosis. Nucleic Acids
Res. 33:1290–1297. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zhu S, Si ML, Wu H and Mo YY: MicroRNA-21
targets the tumor suppressor gene tropomyosin 1 (TPM1). J Biol
Chem. 282:14328–14336. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Lawrie CH, Gal S, Dunlop HM, Pushkaran B,
Liggins AP, Pulford K, Banham AH, Pezzella F, Boultwood J,
Wainscoat JS, et al: Detection of elevated levels of
tumour-associated microRNAs in serum of patients with diffuse large
B-cell lymphoma. Br J Haematol. 141:672–675. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Li CH, Fu R, Wang YH, Song WJ, Ruan EB, Qu
W, Wang HQ, Wang GJ, Song J, Wang XM, et al: Expression and
clinical significance of miR-21 in diffuse large B cell lymphoma.
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 22:339–343. 2014.(In Chinese).
PubMed/NCBI
|
|
38
|
O'Donnell KA, Wentzel EA, Zeller KI, Dang
CV and Mendell JT: c-Myc regulated microRNAs modulate E2F1
expression. Nature. 435:839–843. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
He L, Thomson JM, Hemann MT,
Hernando-Monge E, Mu D, Goodson S, Powers S, Cordon-Cardo C, Lowe
SW, Hannon GJ and Hammond SM: A microRNA polycistron as a potential
human oncogene. Nature. 435:828–833. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Lawrie CH, Chi J, Taylor S, Tramonti D,
Ballabio E, Palazzo S, Saunders NJ, Pezzella F, Boultwood J,
Wainscoat JS and Hatton CS: Expression of microRNAs in diffuse
large B cell lymphoma is associated with immunophenotype, survival
and transformation from follicular lymphoma. J Cell Mol Med.
13:1248–1260. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Ventura A, Young AG, Winslow MM, Lintault
L, Meissner A, Erkeland SJ, Newman J, Bronson RT, Crowley D, Stone
JR, et al: Targeted deletion reveals essential and overlapping
functions of the miR-17 through 92 family of miRNA clusters. Cell.
132:875–886. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Chen W, Houldsworth J, Olshen AB,
Nanjangud G, Chaganti S, Venkatraman ES, Halaas J, Teruya-Feldstein
J, Zelenetz AD and Chaganti RS: Array comparative genomic
hybridization reveals genomic copy number changes associated with
outcome in diffuse large B-cell lymphomas. Blood. 107:2477–2485.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Tam W: Micro-classifying diffuse large
B-cell lymphomas. Blood. 113:6506–6507. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Hayashita Y, Osada H, Tatematsu Y, Yamada
H, Yanagisawa K, Tomida S, Yatabe Y, Kawahara K, Sekido Y and
Takahashi T: A polycistronic microRNA cluster, miR-17–92, is
overexpressed in human lung cancers and enhances cell
proliferation. Cancer Res. 65:9628–9632. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Thapa DR, Li X, Jamieson BD and
Martínez-Maza O: Overexpression of microRNAs from the miR-17–92
paralog clusters in AIDS-related non-Hodgkin's lymphomas. PLoS One.
6:e207812011. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Xiao C, Calado DP, Galler G, Thai TH,
Patterson HC, Wang J, Rajewsky N, Bender TP and Rajewsky K: MiR-150
controls B cell differentiation by targeting the transcription
factor c-Myb. Cell. 131:146–159. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Tan LP, Wang M, Robertus JL, Schakel RN,
Gibcus JH, Diepstra A, Harms G, Peh SC, Reijmers RM, Pals ST, et
al: MiRNA profiling of B-cell subsets: Specific miRNA profile for
germinal center B cells with variation between centroblasts and
centrocytes. Lab Invest. 89:708–716. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Tober J, McGrath KE and Palis J: Primitive
erythropoiesis and megakaryopoiesis in the yolk sac are independent
of c-myb. Blood. 111:2636–2639. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Calin GA, Cimmino A, Fabbri M, Ferracin M,
Wojcik SE, Shimizu M, Taccioli C, Zanesi N, Garzon R, Aqeilan RI,
et al: MiR-15a and miR-16-1 cluster functions in human leukemia.
Proc Natl Acad Sci USA. 105:5166–5171. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Alencar AJ, Malumbres R, Kozloski GA,
Advani R, Talreja N, Chinichian S, Briones J, Natkunam Y, Sehn LH,
Gascoyne RD, et al: MicroRNAs are independent predictors of outcome
in diffuse large B-cell lymphoma patients treated with R-CHOP. Clin
Cancer Res. 17:4125–4135. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Pasqualucci L, Compagno M, Houldsworth J,
Monti S, Grunn A, Nandula SV, Aster JC, Murty VV, Shipp MA and
Dalla-Favera R: Inactivation of the PRDM1/BLIMP1 gene in diffuse
large B cell lymphoma. J Exp Med. 203:311–317. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Chen R, Alvero AB, Silasi DA, Kelly MG,
Fest S, Visintin I, Leiser A, Schwartz PE, Rutherford T and Mor G:
Regulation of IKKbeta by miR-199a affects NF-kappaB activity in
ovarian cancer cells. Oncogene. 27:4712–4723. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Al-Katib A, Arnold AA, Aboukameel A, Sosin
A, Smith P, Mohamed AN, Beck FW and Mohammad RM: I-kappa-kinase-2
(IKK-2) inhibition potentiates vincristine cytotoxicity in
non-Hodgkin's lymphoma. Mol Cancer. 9:2282010. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Jima DD, Zhang J, Jacobs C, Richards KL,
Dunphy CH, Choi WW, Au WY, Srivastava G, Czader MB, Rizzieri DA, et
al: Deep sequencing of the small RNA transcriptome of normal and
malignant human B cells identifies hundreds of novel microRNAs.
Blood. 116:e118–e127. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Montes-Moreno S, Martinez N,
Sanchez-Espiridión B, Uriarte Díaz R, Rodriguez ME, Saez A,
Montalbán C, Gomez G, Pisano DG, García JF, et al: MiRNA expression
in diffuse large B-cell lymphoma treated with chemoimmunotherapy.
Blood. 118:1034–1040. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
López AN and Pous LH: MicroRNAs in
lymphoma. MicroRNAs in Cancer Translational Research. Cho WCS:
(Netherlands, Heidelberg). Springer. 239–267. 2011. View Article : Google Scholar
|
|
57
|
Shen J, Liu Z, Todd NW, Zhang H, Liao J,
Yu L, Guarnera MA, Li R, Cai L, Zhan M and Jiang F: Diagnosis of
lung cancer in individuals with solitary pulmonary nodules by
plasma microRNA biomarkers. BMC Cancer. 11:3742011. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Fassina A, Marino F, Siri M, Zambello R,
Ventura L, Fassan M, Simonato F and Cappellesso R: The miR-17–92
microRNA cluster: A novel diagnostic tool in large B-cell
malignancies. Lab Invest. 92:1574–1582. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Baraniskin A, Kuhnhenn J, Schlegel U, Chan
A, Deckert M, Gold R, Maghnouj A, Zöllner H, Reinacher-Schick A,
Schmiegel W, et al: Identification of microRNAs in the
cerebrospinal fluid as marker for primary diffuse large B-cell
lymphoma of the central nervous system. Blood. 117:3140–3146. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Robertus JL, Harms G, Blokzijl T, Booman
M, de Jong D, van Imhoff G, Rosati S, Schuuring E, Kluin P and van
den Berg P: Specific expression of miR-17-5p and miR-127 in
testicular and central nervous system diffuse large B-cell
lymphoma. Mod Pathol. 22:547–555. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Culpin RE, Proctor SJ, Angus B, Crosier S,
Anderson JJ and Mainou-Fowler T: A 9 series microRNA signature
differentiates between germinal centre and activated B-cell-like
diffuse large B-cell lymphoma cell lines. Int J Oncol. 37:367–376.
2010.PubMed/NCBI
|
|
62
|
Cao QW, Li HY, Yao XX and Wang JF:
Significance of microRNA-146b-5p in diffuse large B-cell lymphoma
and its relationship with risk assessment. Zhonghua Xue Ye Xue Za
Zhi. 33:1010–1014. 2012.(In Chinese). PubMed/NCBI
|
|
63
|
Felli N, Fontana L, Pelosi E, Botta R,
Bonci D, Facchiano F, Liuzzi F, Lulli V, Morsilli O, Santoro S, et
al: MicroRNAs 221 and 222 inhibit normal erythropoiesis and
erythroleukemic cell growth via kit receptor down-modulation. Proc
Natl Acad Sci USA. 102:18081–18086. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Le Sage C, Nagel R, Egan DA, Schrier M,
Mesman E, Mangiola A, Anile C, Maira G, Mercatelli N, Ciafrè SA, et
al: Regulation of the p27(Kip1) tumor suppressor by miR-221 and
miR-222 promotes cancer cell proliferation. EMBO J. 26:3699–3708.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Bishton MJ, Hughes S, Richardson F, James
E, Bessell E, Sovani V, Ganatra R, Haynes AP, McMillan AK and Fox
CP: Delineating outcomes of patients with diffuse large B cell
lymphoma using the National Comprehensive Cancer
Network-International Prognostic Index and Positron Emission
Tomography-defined Remission Status; A population-based analysis.
Br J Haematol: Nov. 18:2015.(Epub ahead of print).
|
|
66
|
Chen W, Wang H, Chen H, Liu S, Lu H, Kong
D, Huang X, Kong Q and Lu Z: Clinical significance and detection of
microRNA-21 in serum of patients with diffuse large B-cell lymphoma
in Chinese population. Eur J Haematol. 92:407–412. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K,
Guo J, Zhang Y, Chen J, Guo X, et al: Characterization of microRNAs
in serum: A novel class of biomarkers for diagnosis of cancer and
other diseases. Cell Res. 18:997–1006. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Mitchell PS, Parkin RK, Kroh EM, Fritz BR,
Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O'Briant
KC, Allen A, et al: Circulating microRNAs as stable blood-based
markers for cancer detection. Proc Natl Acad Sci USA.
105:10513–10518. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Gilad S, Meiri E, Yogev Y, Benjamin S,
Lebanony D, Yerushalmi N, Benjamin H, Kushnir M, Cholakh H, Melamed
N, et al: Serum microRNAs are promising novel biomarkers. PloS One.
3:e31482008. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Ohyashiki K, Umezu T, Yoshizawa S, Ito Y,
Ohyashiki M, Kawashima H, Tanaka M, Kuroda M and Ohyashiki JH:
Clinical impact of down-regulated plasma miR-92a levels in
non-Hodgkin's lymphoma. Plos One. 6:e164082011. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Song G, Gu L, Li J, Tang Z, Liu H, Chen B,
Sun X, He B, Pan Y, Wang S and Cho WC: Serum microRNA expression
profiling predict response to R-CHOP treatment in diffuse large B
cell lymphoma patients. Ann Hematol. 93:1735–1743. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Saito Y, Liang G, Egger G, Friedman JM,
Chuang JC, Coetzee GA and Jones PA: Specific activation of
microRNA-127 with downregulation of the proto-oncogene BCL6 by
chromatin-modifying drugs in human cancer cells. Cancer Cell.
9:435–443. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Seshadri T, Kuruvilla J, Crump M and
Keating A: Salvage therapy for relapsed/refractory diffuse large B
cell lymphoma. Biol Blood Marrow Transplant. 14:259–267. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Lee JW, Choi CH, Choi JJ, Park YA, Kim SJ,
Hwang SY, Kim WY, Kim TJ, Lee JH, Kim BG and Bae DS: Altered
MicroRNA Expression in Cervical Carcinomas. Clin Cancer Res.
14:2535–2542. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Trang P, Medina PP, Wiggins JF, Ruffino L,
Kelnar K, Omotola M, Homer R, Brown D, Bader AG, Weidhaas JB and
Slack FJ: Regression of murine lung tumors by the let-7 microRNA.
Oncogene. 29:1580–1587. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Vester B and Wengel J: LNA (Locked nucleic
acid): Highaffinity targeting of complementary RNA and DNA.
Biochemistry. 43:13233–13241. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Elmén J, Lindow M, Schütz S, Lawrence M,
Petri A, Obad S, Lindholm M, Hedtjärn M, Hansen HF, Berger U, et
al: LNA-mediated microRNA silencing in non-human primates. Nature.
452:896–899. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Hammond SM: Soaking up small RNAs. Nat
Methods. 4:694–695. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Bonci D, Coppola V, Musumeci M, Addario A,
Giuffrida R, Memeo L, D'Urso L, Pagliuca A, Biffoni M, Labbaye C,
et al: The miR-15a-miR-16-1 cluster controls prostate cancer by
targeting multiple oncogenic activities. Nat Med. 14:1271–1277.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Bai H, Wei J, Deng C, Yang X, Wang C and
Xu R: MicroRNA-21 regulates the sensitivity of diffuse large B-cell
lymphoma cells to the CHOP chemotherapy regimen. Int J Hematol.
97:223–231. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Gu L, Song G, Chen L, Nie Z, He B, Pan Y,
Xu Y, Li R, Gao T, Cho WC and Wang S: Inhibition of miR-21 induces
biological and behavioral alterations in diffuse large B-cell
lymphoma. Acta Haematol. 130:87–94. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Sud R and Friedberg JW: Salvage therapy
for relapsed or refractory diffuse large B-cell lymphoma: Impact of
prior rituximab. Haematologica. 93:1776–1780. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Rao E, Jiang C, Ji M, Huang X, Iqbal J,
Lenz G, Wright G, Staudt LM, Zhao Y, McKeithan TW, et al: The
miRNA-17~92 cluster mediates chemoresistance and enhances tumor
growth in mantle cell lymphoma via PI3K/AKT pathway activation.
Leukemia. 26:1064–1072. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Shringarpure R, Catley L, Bhole D, Burger
R, Podar K, Tai YT, Kessler B, Galardy P, Ploegh H, Tassone P, et
al: Gene expression analysis of B-lymphoma cells resistant and
sensitive to bortezomib. Br J Haematol. 134:145–156. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Ling H, Fabbri M and Calin GA: MicroRNAs
and other non-coding RNAs as targets for anticancer drug
development. Nat Rev Drug Discov. 12:847–865. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Janssen HL, Reesink HW, Lawitz EJ, Zeuzem
S, Rodriguez-Torres M, Patel K, van der Meer AJ, Patick AK, Chen A,
Zhou Y, et al: Treatment of HCV infection by targeting microRNA. N
Engl J Med. 368:1685–1694. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Berglund M, Thunberg U, Amini RM, Book M,
Roos G, Erlanson M, Linderoth J, Dictor M, Jerkeman M,
Cavallin-Ståhl E, et al: Evaluation of immunophenotype in diffuse
large B-cell lymphoma and its impact on prognosis. Mod Pathol.
18:1113–1120. 2005. View Article : Google Scholar : PubMed/NCBI
|
